Stephen Appezzato

Miranda Delatore and Megan Wetzel share their outlook on the future of specialty pharmacy.

In this week's Pharma Pulse, Eli Lilly opens its new genetic medicine plant, Bayer acquires Perfuse Therapeutics, and more.

Jessica Lovett discusses specialty pharma commercialization timelines, and how the Canadian market is different from the US.

The facility opening corresponds with a new $4.5 billion capital commitment across two of Lilly's three sites in Lebanon, Indiana.

Tommy Bramley explains how real-world evidence can be leveraged to benefit patient outcomes in specialty pharma.

Live from Asembia AXS26, Austin Russian explains how access to rare disease treatments can be delayed.

Bill McElnea and Hinal Sharma discuss the evolving role of a specialty pharmacy.

Kieran Daly explains how adherence and proof of use strategies improve commercial outcomes and the patient experience in specialty pharma.

Kim Plesnarski explains what the biggest inefficiencies are in specialty pharma partnerships.

Joel Wayment discusses how the cold chain can be more sustainable.

GoodRx now offers oral Ozempic as an alternative to injectable GLP-1 therapies.

Jennifer Lospinoso explains how cell and gene therapies are reshaping specialty pharmacy commercialization.

In this week’s Pharma Pulse, the launch of the Ember Cube 2, exclusive policy insights from Asembia AXS26, a record-breaking prescription spending outlook for 2026 and more.

CoverMyMeds' Miranda Delatore and Megan Wetzel discuss AI in prior auth and fixing specialty access bottlenecks upstream.

Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years.

Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines.

Joel Wayment discusses the implications of the growing cell and gene therapy market on pharma supply chains.

Nico Vandaele shares how advanced modeling and simulations can be used to get ahead of future supply chain disruptions.

Raquel Vazquez discusses how data can be incorporated to make key decisions within the cold chain.

Joydeep Ganguly evaluates 4IR tools, data strategy, and why end-to-end thinking will define pharma supply chain transformation.

Shawn McGee discusses today's key risks in the pharma supply chain, and how to prevent disruptions.

In this week’s Pharma Pulse, GEODIS’ cold chain expansion in the Midwest, a potential multi-billion dollar shift in cell therapy, and the White House’s new push for psychedelic mental health treatments.

The facility opening coincides with rapid growth projections for the pharmaceutical cold chain industry in the coming years.

Anthony "TJ" Rizzo explains how modern tools are enabling more oversight and precision within the cold chain.

Identiv's ID-Safe portfolio expands NFC authentication and tamper detection to secure pharmaceutical supply chains against counterfeiting and fraud.

Ahead of LogiPharma Europe 2026, Richard Harrop explains why packaging must be more patient-centric.

Pharma importers can apply for tariff reimbursements through the US Customs and Border Protection’s online portal.

Anthony “TJ” Rizzo shares his outlook on the future of pharma cold chain technology.

Fran Gregory, VP of Emerging Therapies at Cardinal Health, discusses key findings from the company's 2026 Advanced Therapy Report.